Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GH Research PLC stock logo
GHRS
GH Research
$12.78
+1.8%
$13.86
$6.00
$20.50
$652.95M0.98408,498 shs106,984 shs
Jushi Holdings Inc. stock logo
JUSHF
Jushi
$0.64
+21.9%
$0.45
$0.22
$0.98
$102.77M-0.98709,713 shs430,956 shs
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$12.91
+0.8%
$13.40
$7.30
$16.32
$639.91M0.05843,063 shs577,137 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.58
+2.2%
$4.24
$2.45
$6.71
$568.32M1.76711,644 shs356,124 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GH Research PLC stock logo
GHRS
GH Research
-0.95%+3.38%-28.57%+6.45%+18.73%
Jushi Holdings Inc. stock logo
JUSHF
Jushi
-14.23%-22.36%+37.92%+58.18%-21.54%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-3.97%+4.57%-16.76%+7.92%+4.66%
Organogenesis stock logo
ORGO
Organogenesis
-2.18%-8.38%+2.52%+48.84%+67.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GH Research PLC stock logo
GHRS
GH Research
2.5182 of 5 stars
3.43.00.00.03.90.80.0
Jushi Holdings Inc. stock logo
JUSHF
Jushi
2.0087 of 5 stars
0.05.00.00.03.41.70.6
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
4.0906 of 5 stars
3.61.00.04.43.21.70.6
Organogenesis stock logo
ORGO
Organogenesis
4.2717 of 5 stars
3.31.00.04.32.74.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GH Research PLC stock logo
GHRS
GH Research
2.88
Moderate Buy$32.00150.39% Upside
Jushi Holdings Inc. stock logo
JUSHF
Jushi
1.00
SellN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3.11
Buy$26.29103.61% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5063.76% Upside

Current Analyst Ratings Breakdown

Latest JUSHF, KALV, ORGO, and GHRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
GH Research PLC stock logo
GHRS
GH Research
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
7/8/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $27.00
7/8/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $27.00
7/7/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$18.00 ➝ $20.00
6/24/2025
GH Research PLC stock logo
GHRS
GH Research
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$39.00
6/4/2025
GH Research PLC stock logo
GHRS
GH Research
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GH Research PLC stock logo
GHRS
GH Research
N/AN/AN/AN/A$5.83 per shareN/A
Jushi Holdings Inc. stock logo
JUSHF
Jushi
$257.52M0.49N/AN/A($0.40) per share-1.59
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/A$1.92 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.21$0.21 per share21.95$1.84 per share2.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GH Research PLC stock logo
GHRS
GH Research
-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%9/2/2025 (Estimated)
Jushi Holdings Inc. stock logo
JUSHF
Jushi
-$48.78M-$0.29N/AN/AN/A-22.56%N/A-13.23%11/6/2025 (Estimated)
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$183.44M-$3.69N/AN/AN/AN/A-134.07%-82.65%9/4/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%N/A

Latest JUSHF, KALV, ORGO, and GHRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2025Q1 2026
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$0.91N/AN/AN/A$1.97 millionN/A
9/2/2025Q2 2025
GH Research PLC stock logo
GHRS
GH Research
-$0.22N/AN/AN/AN/AN/A
8/7/2025Q2 2025
GH Research PLC stock logo
GHRS
GH Research
-$0.22-$0.15+$0.07-$0.15N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/5/2025Q2 2025
Jushi Holdings Inc. stock logo
JUSHF
Jushi
-$0.06-$0.06N/A-$0.06$64.67 million$65.05 million
7/10/2025Q4 2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$0.83-$3.69-$2.86-$0.99$4.20 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GH Research PLC stock logo
GHRS
GH Research
N/AN/AN/AN/AN/A
Jushi Holdings Inc. stock logo
JUSHF
Jushi
N/AN/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GH Research PLC stock logo
GHRS
GH Research
N/A
29.49
29.49
Jushi Holdings Inc. stock logo
JUSHF
Jushi
N/A
1.02
0.48
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
5.35
5.35
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45

Institutional Ownership

CompanyInstitutional Ownership
GH Research PLC stock logo
GHRS
GH Research
56.90%
Jushi Holdings Inc. stock logo
JUSHF
Jushi
21.68%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
Organogenesis stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
GH Research PLC stock logo
GHRS
GH Research
41.60%
Jushi Holdings Inc. stock logo
JUSHF
Jushi
21.66%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
10.50%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
GH Research PLC stock logo
GHRS
GH Research
1052.03 millionN/AOptionable
Jushi Holdings Inc. stock logo
JUSHF
Jushi
1,234196.70 million154.09 millionNot Optionable
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
10049.95 million44.71 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable

Recent News About These Companies

Organogenesis Amends Credit Agreement Amid Revenue Decline
ORGO Sales Drop 23%
Organogenesis Holdings Inc. (ORGO) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
GH Research stock logo

GH Research NASDAQ:GHRS

$12.78 +0.23 (+1.83%)
Closing price 04:00 PM Eastern
Extended Trading
$12.65 -0.13 (-1.02%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Jushi stock logo

Jushi OTCMKTS:JUSHF

$0.64 +0.11 (+21.89%)
As of 03:58 PM Eastern

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

KalVista Pharmaceuticals stock logo

KalVista Pharmaceuticals NASDAQ:KALV

$12.91 +0.10 (+0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$12.99 +0.08 (+0.62%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.58 +0.10 (+2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$4.62 +0.04 (+0.96%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.